Antibody Glycoengineering

CD BioGlyco can customize one-stop services for glycoengineered antibodies according to customers' R&D or cGMP production needs. We have confidence to be your essential research assistant in the field of glycobiology. 

Background

Monoclonal antibodies (mAbs) are currently the largest and fastest-growing category of biopharmaceuticals. Since 1984, more than 60 mAbs and fusion molecules has been approvedfor use in more than 30 cancers, autoimmune and cardiovascular diseases. It is estimated that by 2024, the global market value of mAbs will reach 138.6 billion dollars.

The clinical efficacy and safety of mAbs are affected by their glycosylation structure and composition. Glycosyl distribution is usually heterogeneous, depends largely on the manufacturing process, and is therefore susceptible to changes in cell culture conditions. Therefore, it is considered a key quality attribute of mAbs. Great efforts have been made in mammalian and non-mammalian cells to control the glycosylation of mAbs. However, it is still a challenge to obtain a specific glycoform that is completely homogeneous.

The latest innovations in chemoenzymatic glycoengineering technology will allow the production of mAbs with well-defined and uniform Fc glycoforms, thereby giving them the desired biological properties. This method has significant advantages, such as enhanced Fc effector function, improved safety, higher batch-to-batch consistency, reduced immunogenicity, and can be expressed economically. Overall, producing mAbs with the innovative glycoengineering technology will bring tangible benefits to patients and manufacturers.

Fig 1. Schematic structure of common IgG antibodies (Wang, L.; et al. 2019)

Services

Mammalian host systems are the preferred expression platform because they can maximize the post-translational processing and functional activity of proteins.

• CD BioGlyco provides the most prominent host cell lines for commercially available products: Chinese Hamster Ovary (CHO) or Mouse Myeloma (NS0, SP2/0) cell lines, and other cell lines. We have carried out glycoengineering of different cell lines, and strictly controlled and optimized environmental factors and cell culture conditions.

Chemoenzymatic glycoengineering refers to the in vitro remodeling of glycans using enzymes such as endoglycosidase and sugar synthase.

• The solution we provide usually includes three steps: Deglycosylation of IgG by endo β-N-acetylglucosaminidase (ENGase, such as Endo S), while retaining the innermost GlcNAc at N297; the oxazoline derivatives with customized N-linked glycan structure as sugar donors are prepared by chemical methods; transglycosylation of the glycan oxazoline donor to the innermost GlcNAc acceptor.

Applications

• Functional optimization of therapeutic antibodies
• Commercialization of antibodies
• Development of new antibody drugs
• Glycoprotein structure and function research

Advantages of Us

• Design, expression, analysis one-stop service
• Highly specific to Fc N-glycans
• Customize experimental programs according to different research needs
• High quality and low cost
• A vast number of services available

CD BioGlyco has experienced scientists and the most advanced technology platforms, which can provide customers with tailor-made services in the design and expression of glycoengineered antibodies, and our powerful analysis platform will provide a guarantee for the final products.

If you are interested in our services, please contact us for more detailed information.

References:

1. Wang, L.; et al. Glycoengineering of antibodies for modulating functions. Annual Review of Biochemistry. 2019, 88(26): 1-27.
2. Li, W.; et al. Crystallizable fragment glycoengineering for therapeutic antibodies development. Frontiers in Immunology. 2017, 8.